Related Experiment Videos
Effects of statins on renal function
1Indiana University School of Medicine, Richard L. Roudebush [corrected] VA Medical Center, 1481 W Tenth St (111N), Indianapolis, IN 46202, USA.
Insights
Statins may slow kidney function decline and reduce protein in urine for chronic kidney disease (CKD) patients. Further research is needed to confirm cardiovascular benefits in this high-risk population.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Patients with chronic kidney disease (CKD) face a higher risk of cardiovascular disease (CVD) mortality.
- Dyslipidemia is common in CKD, potentially worsening cardiovascular risk and disease progression.
- Statins, used for lipid reduction, may offer kidney protection through cholesterol-dependent and independent pathways.
Purpose of the Study:
- To review the evidence on statin therapy's effects on kidney function and proteinuria in CKD patients.
- To assess the current understanding of statins' role in reducing cardiovascular risk in CKD.
- To highlight the need for further research on cardiovascular outcomes in CKD patients using statins.
Main Methods:
- Review of subgroup analyses from major clinical trials.
- Meta-analyses of smaller clinical trials involving statin therapy in CKD.
- Examination of existing literature on statins, dyslipidemia, and cardiovascular outcomes in CKD.
Main Results:
- Statin therapy appears to slow the decline of glomerular filtration rate (GFR) in CKD patients.
- Evidence suggests statins can reduce proteinuria in individuals with CKD.
- Statins are known to decrease cardiovascular morbidity and mortality in various populations, but conclusive data for CKD is pending.
Conclusions:
- Statins show promise in preserving kidney function and reducing proteinuria in CKD.
- While statins benefit cardiovascular health broadly, their specific impact on cardiovascular outcomes in CKD requires more investigation.
- Ongoing studies are crucial for establishing the role of statins in managing cardiovascular risk for CKD patients.
Abstract:
Patients with chronic kidney disease (CKD) are much more likely to die of cardiovascular disease than end-stage renal disease. Dyslipidemia is highly prevalent in patients with CKD and may contribute to the elevated cardiovascular risk as well as CKD progression. Statins are lipid-lowering drugs that appear to protect the kidneys via cholesterol reduction as well as noncholesterol-mediated mechanisms. Subgroup analyses of major clinical studies and meta-analyses of smaller trials indicate that statin therapy slows the decline of the glomerular filtration rate. Additionally, statins appear to reduce proteinuria in patients with CKD. Statins are well recognized to reduce cardiovascular morbidity and mortality in patients with and without documented cardiovascular disease and in certain high-risk populations, such as persons with diabetes mellitus. However, conclusive evidence for improved cardiovascular outcomes with statin therapy for CKD is not yet available. Several ongoing studies are evaluating the effect of statins on cardiovascular end points in patients with CKD and may provide data needed to support adjunctive use of these agents in this high-risk population.
Related Concept Videos
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Serum Studies: Renal Function Tests